Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

BioStock: New positive results for Curasight in brain cancer

Curasight

Curasight's recently announced preclinical results showed uTREAT's potential in inhibiting glioblastoma growth. Adding to this milestone, the company has now also announced encouraging phase II results for uTRACE, demonstrating its prognostic value for survival outcomes in primary glioblastoma patients. BioStock contacted CEO Ulrich Krasilnikoff to learn more about what this means for the company.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/06/new-positive-results-for-curasight-in-brain-cancer/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.